Dual incorporation of photoaffinity ligands on dopamine transporters implicates proximity of labeled domains

Molecular Pharmacology

Volumn 59, Issue 5, 2001, Pages 1157-1164

  Vaughan, Roxanne A ^a   Gaffaney, Jon D ^a   Lever, John R ^b   Reith, Maarten E A ^c   Dutta, Aloke K ^d  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 (DIPHENYLMETHOXY)ETHYL] 1 [(4 AZIDO 3 IODOPHENYL)METHYL]PIPERIDINE; BENZATROPINE; COCAINE; DOPAMINE TRANSPORTER; IODINE 125; PIPERIDINE DERIVATIVE; UNCLASSIFIED DRUG; VANOXERINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; IMMUNOPRECIPITATION; LIGAND BINDING; NONHUMAN; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; RAT; STRUCTURE ACTIVITY RELATION;

EID: 0035027537     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.59.5.1157     Document Type: Article

References (39)

1. Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter
2. High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis
3. Characterization of the azidopine and vinblastine binding site of P-glycoprotein
4. Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium
5. Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants
6. Cocaine receptor: Biochemical characterization and structure-activity relationship of cocaine analogues at the dopamine transporter
7. Permeation and gating residues in serotonin transporter
8. The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding
9. Evidence for two non-identical drug-interaction sites in the human P-glycoprotein
10. Highly selective, novel analogs of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine for the dopamine transporter: Effect of different aromatic substitutions on their affinity and selectivity
11. Potent and selective ligands for the dopamine transporter (DAT): Structure-activity relationship studies of novel 4-[2-(diphenylmethoxy)ethyl]-1-(3-phenylpropyl)piperidine analogues
12. Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogs: Evaluation of behavioral activity of O-and N-analogs and their binding to monoamine transporters
13. Design, synthesis and characterization of 4-[2-(diphenylmethoxy)ethyl]-1-benzyl piperidine, a novel dopamine transporter photoaffinity label
14. Structure-activity relationship studies of novel 4-[2-[bis(4-fluorophenyl)methoxy]ethyl]-1-(3-phenylpropyl)piperidine analogs: Synthesis and biological evaluation at the dopamine and serotonin transporter sites
15. Tolerance in the replacement of the benzhydrylic O-atom in 4-[2-(diphenyl-methoxy)ethyl]-1-benzylpiperidine derivatives by an N-atom: Development of new-generation potent and selective N-analog molecules for the dopamine transporter
16. A putative model of the dopamine transporter
17. Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter
18. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters
19. Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12
20. Differential relationships among dopamine transporter affinities and stimulant potencies of various uptake inhibitors
21. Oligomerization of serotonin transporter and its functional consequences
22. The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its relevance to Parkinson's disease
23. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding
24. The dopamine hypothesis of the reinforcing properties of cocaine
25. Importance of valine at position 152 for the substrate transport and 2β-carbomethoxy-3β-(4-fluorophenyl) tropane binding of dopamine transporter
26. 125I]-RTI-82)
27. Dopamine transporter proline mutations influence dopamine uptake, cocaine analog recognition and expression
28. Dopamine transporter transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition
29. Defining proximity relationships in the tertiary structure of the dopamine transporter
30. 3H]2β-carbomethoxy-3β-(4-fluorophenyl)tropane
31. The dopamine transporter in human brain. Characterization and effect of cocaine exposure
32. The structure and function of norepinephrine, dopamine, and serotonin transporters
33. 3H]GBR 12,935
34. Cocaine and GBR 12909 produce equivalent motoric responses at different occupancy of the dopamine transporter
35. 125I]2-N-[(3′-iodo-4′-azidophenyl)propionyl] tetrabenazine binding sites for the synaptic vesicle monoamine transporter
36. Photoaffinity-labeled ligand binding domains on dopamine transporters identified by peptide mapping
37. Differential binding of tropane-based photoaffinity ligands on the dopamine transporter
38. Dopamine transporter ligand binding domains: Structural and functional properties revealed by limited proteolysis
39. QSAR and CoMFA study of cocaine analogs: Crystal and molecular structure of (-) cocaine hydrochloride and n-methyl-3β-(p-fluorophenyl)tropane-2β-carboxylic acid methyl ester